CMRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-03-14), Chimerix's share price is $8.46. Chimerix's GF Value is $2.02. Therefore, Chimerix's Price-to-GF-Value for today is 4.19. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Chimerix is Significantly Overvalued.
The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.
To calculate this value, GuruFocus follows these steps:
GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.
Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.
Chimerix (NAS:CMRX) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:
Posssible Evaluations | All-in-One Screener Examples (2) |
Possible Value Trap, Think Twice (1) | Predictable Companies that possibly be Value Traps |
Significantly Overvalued | Predictable Companies which are Significantly Overvalued |
Modestly Overvalued | Predictable Companies which are Modestly Overvalued |
Fairly Valued | Predictable High Quality Companies which are Fairly Valued |
Modestly Undervalued (3) | Predictable High Quality Companies which are Modestly Undervalued |
Significantly Undervalued (3) | Predictable High Quality Companies which are Significantly Undervalued |
(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.
(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(3) A sufficient margin of safety exists only when the stock is undervalued.
Chimerix's Price-to-GF-Value for today is calculated as
Price-to-GF-Value | = | Share Price | / | GF Value |
= | 8.46 | / | 2.02 | |
= | 4.19 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Chimerix's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Allen S. Melemed | officer: Chief Medical Officer | C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713 |
David Jakeman | officer: Principal Accounting Officer | C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713 |
Michael Albert Alrutz | officer: Principal Executive Officer | 2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713 |
Michael T. Andriole | officer: Chief Business Officer | C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906 |
Fred A Middleton | director | 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708 |
Michael A. Sherman | director, officer: Chief Executive Officer | 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906 |
Martha J Demski | director | 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122 |
Robert J. Meyer | director | 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713 |
Cantex Pharmaceuticals, Inc. | 10 percent owner | 1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326 |
Victoria Vakiener | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139 |
Pratik S Multani | director | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
William Garrett Nichols | officer: Chief Medical Officer | C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494 |
M Michelle Berrey | officer: Chief Medical Officer | 303A COLLEGE ROAD EAST, PRINCETON NJ 08450 |
Ernest Mario | director | 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928 |
Ed Greissing | director | 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713 |
From GuruFocus
By GuruFocus Research • 03-01-2024
By Marketwired • 02-18-2025
By GuruFocus News • 11-08-2024
By Marketwired • 07-05-2024
By GuruFocus News • 11-08-2024
By Marketwired • 01-24-2025
By Marketwired • 12-09-2024
By Marketwired • 04-24-2024
By Marketwired • 10-18-2024
By Marketwired • 11-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.